Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer.
Gomes I, de Almeida BP, Dâmaso S, Mansinho A, Correia I, Henriques S, Cruz-Duarte R, Vilhais G, Félix P, Alves P, Corredeira P, Barbosa-Morais NL, Costa L, Casimiro S.
Gomes I, et al.
Oncotarget. 2020 May 12;11(19):1714-1728. doi: 10.18632/oncotarget.27576. eCollection 2020 May 12.
Oncotarget. 2020.
PMID: 32477461
Free PMC article.